Compare Cassava Sciences Inc (FLNA) vs Newmont Corporation (NEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Newmont Corporation — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while Newmont Corporation trades at $91.36 (market cap $101.64B). The key difference: Newmont Corporation is far larger — about 1912.7× Cassava Sciences Inc's market cap, and Newmont Corporation pays a 1.09% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | NEM | |
|---|---|---|
Market Cap | $53.14M | $101.64B |
Sector | Health | Basic Materials |
52-Week High | $4.64 | $131.95 |
52-Week Low | $1.09 | $57.99 |
Enterprise Value | -$33.43M | $98.39B |
Dividend Yield | — | 1.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
Newmont Corporation (NEM) trades at $91.73, down 3.19% over the past day amid gold price volatility. The stock shows strong fundamentals with a P/E of 12.35, net income margin of 33.87%, and three consecutive quarterly earnings beats. Technical indicators are neutral with support at $91 and resistance at $96. Recent news highlights mixed sentiment due to gold's decline but positive long-term outlook from analysts.
NEM presents a compelling value with robust cash flow growth and a bullish analyst consensus (75.68% buy ratings) targeting $140.11. Key risks include higher unit costs pressuring 2026 margins and gold price sensitivity. The stock's current dip may offer entry opportunity given strong fundamentals and institutional support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Newmont Corporation
Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Read more on NEM →
